Mixed Dyslipidemia - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Mixed Dyslipidemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
To access full report with TOC, please visit Mixed Dyslipidemia - Pipeline Review, H1 2016.
- The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia
- The report reviews pipeline therapeutics for Mixed Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews latest news related to pipeline therapeutics for Mixed Dyslipidemia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Amgen Inc. CymaBay Therapeutics, Inc. Hanmi Pharmaceuticals, Co. Ltd. Matinas BioPharma Holdings, Inc. Pfizer Inc. Thetis Pharmaceuticals LLC
Manager - Marketing
Reportstack Market Research